IQVIA (IQV) Competitors

$231.18
-3.82 (-1.63%)
(As of 05/17/2024 08:53 PM ET)

IQV vs. ICLR, INCY, MEDP, CRL, TAK, HUM, IDXX, CNC, ALC, and COR

Should you be buying IQVIA stock or one of its competitors? The main competitors of IQVIA include ICON Public (ICLR), Incyte (INCY), Medpace (MEDP), Charles River Laboratories International (CRL), Takeda Pharmaceutical (TAK), Humana (HUM), IDEXX Laboratories (IDXX), Centene (CNC), Alcon (ALC), and Cencora (COR). These companies are all part of the "medical" sector.

IQVIA vs.

IQVIA (NYSE:IQV) and ICON Public (NASDAQ:ICLR) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, profitability, valuation, risk, earnings, media sentiment and dividends.

IQVIA has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500. Comparatively, ICON Public has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.

IQVIA has a net margin of 9.01% compared to ICON Public's net margin of 8.30%. IQVIA's return on equity of 29.17% beat ICON Public's return on equity.

Company Net Margins Return on Equity Return on Assets
IQVIA9.01% 29.17% 6.65%
ICON Public 8.30%11.70%6.25%

IQVIA has higher revenue and earnings than ICON Public. IQVIA is trading at a lower price-to-earnings ratio than ICON Public, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IQVIA$14.98B2.81$1.36B$7.3231.58
ICON Public$8.12B3.20$612.34M$8.2238.29

IQVIA currently has a consensus price target of $257.57, indicating a potential upside of 11.42%. ICON Public has a consensus price target of $339.44, indicating a potential upside of 7.86%. Given IQVIA's higher possible upside, equities research analysts plainly believe IQVIA is more favorable than ICON Public.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IQVIA
0 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.80
ICON Public
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, IQVIA had 8 more articles in the media than ICON Public. MarketBeat recorded 9 mentions for IQVIA and 1 mentions for ICON Public. IQVIA's average media sentiment score of 0.75 beat ICON Public's score of 0.00 indicating that IQVIA is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IQVIA
6 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
ICON Public
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

89.6% of IQVIA shares are held by institutional investors. Comparatively, 95.6% of ICON Public shares are held by institutional investors. 1.6% of IQVIA shares are held by insiders. Comparatively, 44.0% of ICON Public shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

IQVIA received 40 more outperform votes than ICON Public when rated by MarketBeat users. Likewise, 68.03% of users gave IQVIA an outperform vote while only 64.99% of users gave ICON Public an outperform vote.

CompanyUnderperformOutperform
IQVIAOutperform Votes
634
68.03%
Underperform Votes
298
31.97%
ICON PublicOutperform Votes
594
64.99%
Underperform Votes
320
35.01%

Summary

IQVIA beats ICON Public on 12 of the 18 factors compared between the two stocks.

Get IQVIA News Delivered to You Automatically

Sign up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IQV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IQV vs. The Competition

MetricIQVIACommercial physical research IndustryMedical SectorNYSE Exchange
Market Cap$42.12B$5.36B$4.89B$17.92B
Dividend YieldN/A1.12%44.82%3.42%
P/E Ratio31.5815.38125.2723.22
Price / Sales2.81118.522,466.4010.50
Price / Cash14.6925.8534.4219.21
Price / Book6.903.835.175.66
Net Income$1.36B$130.17M$100.69M$971.51M
7 Day Performance0.93%76.80%117.54%3.48%
1 Month Performance1.35%59.39%124.75%8.34%
1 Year Performance15.91%2.82%134.78%27.36%

IQVIA Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ICLR
ICON Public
2.8358 of 5 stars
$315.57
+2.0%
$339.44
+7.6%
+47.9%$26.03B$8.12B38.3941,100
INCY
Incyte
4.886 of 5 stars
$57.05
-1.0%
$74.93
+31.3%
-10.2%$12.93B$3.77B17.292,524
MEDP
Medpace
4.9212 of 5 stars
$398.52
+2.4%
$443.00
+11.2%
+86.5%$12.35B$1.96B40.625,900
CRL
Charles River Laboratories International
4.5426 of 5 stars
$232.82
+1.9%
$255.27
+9.6%
+11.7%$11.99B$4.13B27.3921,800Analyst Upgrade
TAK
Takeda Pharmaceutical
0.9119 of 5 stars
$13.45
+2.6%
$14.00
+4.1%
-18.3%$42.57B$28.20B24.4549,095Gap Up
HUM
Humana
4.9729 of 5 stars
$344.50
+1.4%
$424.50
+23.2%
-30.6%$41.51B$109.24B21.4567,600
IDXX
IDEXX Laboratories
3.7275 of 5 stars
$521.11
+3.6%
$580.38
+11.4%
+11.3%$43.04B$3.66B50.4511,000Positive News
CNC
Centene
4.5915 of 5 stars
$76.85
-0.4%
$85.23
+10.9%
+19.4%$41.01B$154.00B15.2867,700Analyst Revision
ALC
Alcon
3.0566 of 5 stars
$89.27
+10.3%
$92.15
+3.2%
+8.6%$44.02B$9.46B45.5525,000Earnings Report
High Trading Volume
COR
Cencora
4.1687 of 5 stars
$221.94
-0.4%
$233.90
+5.4%
+28.1%$44.27B$262.17B24.2846,000

Related Companies and Tools

This page (NYSE:IQV) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners